Efpeglenatide
Efpeglenatide is an investigational long-acting GLP-1 receptor agonist. Efpeglenatide is an exendin-4 analog conjugated to a human immunoglobulin Fc fragment through a flexible linker. The Fc domain engages the neonatal Fc receptor recycling pathway, which greatly extends half-life and supports weekly or less frequent dosing, while the exendin portion provides GLP-1 receptor agonism.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- —
- FDA status
- Investigational New Drug (IND)
- Administration Route
- subcutaneous
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
Research summary
Long-acting exendin-based GLP-1 receptor agonist studied for type 2 diabetes and cardiovascular and renal outcomes. Not FDA-approved.
Peptide Library's Efpeglenatide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- —
- Frequency
- —
- Cycle
- —
- Administration Route
- subcutaneous
- Reconstitution Guide
- —
Science
Mechanism of Action
Efpeglenatide is an exendin-4 analog conjugated to a human immunoglobulin Fc fragment through a flexible linker. The Fc domain engages the neonatal Fc receptor recycling pathway, which greatly extends half-life and supports weekly or less frequent dosing, while the exendin portion provides GLP-1 receptor agonism.
Studies
- Impact of baseline FIB-4 score on efpeglenatide benefits on cardiovascular outcomes in people with type 2 diabetes: a participant-level exploratory analysis of the AMPLITUDE-O trial
- Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial
- Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
- Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study
- Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes
Regulatory & research status
Efpeglenatide has been studied under an Investigational New Drug application. It is not approved for marketing.
| FDA status | Investigational New Drug (IND) |
|---|---|
| Research status | Investigational; clinical development reported |
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Clinical Trial |
Benefits
—
Potential Side Effects
No side effects listed yet for this entry.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Efpeglenatide: frequently asked questions
What is Efpeglenatide?
Long-acting exendin-based GLP-1 receptor agonist studied for type 2 diabetes and cardiovascular and renal outcomes. Not FDA-approved.
How does Efpeglenatide work?
Efpeglenatide is an exendin-4 analog conjugated to a human immunoglobulin Fc fragment through a flexible linker. The Fc domain engages the neonatal Fc receptor recycling pathway, which greatly extends half-life and supports weekly or less frequent dosing, while the exendin portion provides GLP-1 receptor agonism.
Is Efpeglenatide FDA approved?
No. Efpeglenatide is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.
What peptides are similar to Efpeglenatide?
Compounds most often compared with Efpeglenatide include Tirzepatide, VK2735, Ecnoglutide and Semaglutide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Impact of baseline FIB-4 score on efpeglenatide benefits on cardiovascular outcomes in people with type 2 diabetes: a participant-level exploratory analysis of the AMPLITUDE-O trial — Cardiovasc Diabetol, 2024External reference
- Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial — Diabetes Care, 2022External reference
- Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes — N Engl J Med, 2021External reference
- Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study — BMJ Open Diabetes Res Care, 2021External reference
- Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes — Diabetes Obes Metab, 2020External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Efpeglenatide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Efpeglenatide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →